Jeffrey M Leiden's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 3,547 Common Stock done at an average price of $485.1 . Disclosure was reported to the exchange on Feb. 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 485.11 per share. | 24 Feb 2026 | 3,547 | 34,797 (0%) | 0% | 485.1 | 1,720,685 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 8,269 | 41,308 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.75 per share. | 17 Feb 2026 | 2,964 | 38,344 (0%) | 0% | 483.8 | 1,433,835 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2026 | 9,012 | 33,039 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 63,781 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.52 per share. | 03 Dec 2025 | 63,781 | 87,807 (0%) | 0% | 86.5 | 5,518,332 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 452.20 per share. | 03 Dec 2025 | 15,681 | 36,456 (0%) | 0% | 452.2 | 7,090,948 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 453.34 per share. | 03 Dec 2025 | 10,360 | 26,096 (0%) | 0% | 453.3 | 4,696,602 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 445.56 per share. | 03 Dec 2025 | 7,899 | 67,298 (0%) | 0% | 445.6 | 3,519,478 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 449.84 per share. | 03 Dec 2025 | 5,880 | 57,946 (0%) | 0% | 449.8 | 2,645,059 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 451.20 per share. | 03 Dec 2025 | 5,809 | 52,137 (0%) | 0% | 451.2 | 2,621,021 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 440.40 per share. | 03 Dec 2025 | 4,469 | 83,338 (0%) | 0% | 440.4 | 1,968,148 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 444.36 per share. | 03 Dec 2025 | 4,352 | 75,197 (0%) | 0% | 444.4 | 1,933,855 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 443.21 per share. | 03 Dec 2025 | 2,469 | 79,549 (0%) | 0% | 443.2 | 1,094,285 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 448.78 per share. | 03 Dec 2025 | 2,320 | 63,826 (0%) | 0% | 448.8 | 1,041,170 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 455.22 per share. | 03 Dec 2025 | 2,070 | 24,026 (0%) | 0% | 455.2 | 942,305 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 441.26 per share. | 03 Dec 2025 | 1,320 | 82,018 (0%) | 0% | 441.3 | 582,463 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 447.05 per share. | 03 Dec 2025 | 1,152 | 66,146 (0%) | 0% | 447.1 | 515,002 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.00 per share. | 03 Dec 2025 | 1 | 24,027 (0%) | 0% | 91 | 91 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2025 | 1 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 39,769 | 63,781 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.52 per share. | 13 Nov 2025 | 39,769 | 77,630 (0%) | 0% | 86.5 | 3,440,814 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 440.30 per share. | 13 Nov 2025 | 32,234 | 45,396 (0%) | 0% | 440.3 | 14,192,630 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 441.35 per share. | 13 Nov 2025 | 21,330 | 24,066 (0%) | 0% | 441.4 | 9,413,996 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.05 per share. | 13 Nov 2025 | 19,688 | 43,714 (0%) | 0% | 91.0 | 1,792,592 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 19,688 | 13,836 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 440.22 per share. | 13 Nov 2025 | 18,528 | 25,186 (0%) | 0% | 440.2 | 8,156,396 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 13,835 | 1 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.05 per share. | 13 Nov 2025 | 13,835 | 37,861 (0%) | 0% | 91.1 | 1,259,677 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 441.05 per share. | 13 Nov 2025 | 1,160 | 24,026 (0%) | 0% | 441.1 | 511,618 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 442.00 per share. | 13 Nov 2025 | 40 | 24,026 (0%) | 0% | 442 | 17,680 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 6,066 | 24,026 (0%) | 0% | 463.5 | 2,811,348 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,209 | 32,617 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 450.83 per share. | 12 Feb 2025 | 2,525 | 30,092 (0%) | 0% | 450.8 | 1,138,346 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 15,414 | 25,408 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 499.00 per share. | 30 Aug 2024 | 3,784 | 9,994 (0%) | 0% | 499 | 1,888,216 | Common Stock |
| Vertex Pharma | Jeffrey Leiden M | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 20 Feb 2024 | 4,118 | 13,778 (0%) | 0% | 420.6 | 1,731,948 | Common Stock |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.16 per share. | 14 Feb 2024 | 4,655 | 17,896 (0%) | 0% | 419.2 | 1,951,190 | Common Stock |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.04 per share. | 14 Feb 2024 | 4,356 | 22,551 (0%) | 0% | 419.0 | 1,825,338 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.22 per share. | 12 Feb 2024 | 2,009 | 28,291 (0%) | 0% | 419.2 | 842,213 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.13 per share. | 12 Feb 2024 | 737 | 26,907 (0%) | 0% | 419.1 | 308,899 | Common Stock |
| Vertex Pharma | Leiden Jeffrey M | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 420.39 per share. | 12 Feb 2024 | 647 | 27,644 (0%) | 0% | 420.4 | 271,992 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 08 Feb 2024 | 8,048 | 30,300 (0%) | 0% | 422.7 | 3,402,212 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 421.73 per share. | 08 Feb 2024 | 2,698 | 38,348 (0%) | 0% | 421.7 | 1,137,828 | Common Stock |
| Vertex Pharma | Jeffrey Leiden M | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 20,452 | 33,339 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 10,464 | 12,887 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,707 | 41,046 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | M Jeffrey Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 419.07 per share. | 08 Jan 2024 | 6,648 | 2,423 (0%) | 0% | 419.1 | 2,785,977 | Common Stock |
| Vertex Pharma | Leiden Jeffrey M | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 399.41 per share. | 13 Dec 2023 | 13,254 | 9,171 (0%) | 0% | 399.4 | 5,293,780 | Common Stock |
| Vertex Pharma | Leiden M Jeffrey | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 400.19 per share. | 13 Dec 2023 | 100 | 9,071 (0%) | 0% | 400.2 | 40,019 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.00 per share. | 05 May 2023 | 1,125 | 35,387 (0%) | 0% | 349 | 392,625 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.38 per share. | 05 May 2023 | 708 | 36,683 (0%) | 0% | 349.4 | 247,361 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.30 per share. | 05 May 2023 | 171 | 36,512 (0%) | 0% | 350.3 | 59,901 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.48 per share. | 02 May 2023 | 4,645 | 43,704 (0%) | 0% | 349.5 | 1,623,335 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 349.22 per share. | 02 May 2023 | 2,008 | 39,891 (0%) | 0% | 349.2 | 701,234 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.53 per share. | 02 May 2023 | 1,800 | 38,091 (0%) | 0% | 350.5 | 630,954 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 350.48 per share. | 02 May 2023 | 1,505 | 42,199 (0%) | 0% | 350.5 | 527,472 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 351.59 per share. | 02 May 2023 | 700 | 37,391 (0%) | 0% | 351.6 | 246,113 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 353.18 per share. | 02 May 2023 | 300 | 41,899 (0%) | 0% | 353.2 | 105,954 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 13,730 | 48,349 (0%) | 0% | 289.1 | 3,969,618 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 13 Feb 2023 | 13,344 | 62,079 (0%) | 0% | 298.3 | 3,979,981 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 34,890 | 68,775 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 31,462 | 33,885 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,226 | 79,001 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 317.83 per share. | 01 Feb 2023 | 3,578 | 75,423 (0%) | 0% | 317.8 | 1,137,196 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2022 | 60,342 | 33,524 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.05 per share. | 25 Jul 2022 | 60,342 | 134,502 (0%) | 0% | 91.0 | 5,494,139 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 282.43 per share. | 25 Jul 2022 | 40,666 | 12,894 (0%) | 0% | 282.4 | 11,485,298 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 281.27 per share. | 25 Jul 2022 | 34,090 | 53,560 (0%) | 0% | 281.3 | 9,588,494 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 280.37 per share. | 25 Jul 2022 | 32,983 | 87,650 (0%) | 0% | 280.4 | 9,247,444 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 279.44 per share. | 25 Jul 2022 | 13,869 | 120,633 (0%) | 0% | 279.4 | 3,875,553 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 283.42 per share. | 25 Jul 2022 | 10,471 | 2,423 (0%) | 0% | 283.4 | 2,967,691 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 289.04 per share. | 13 Apr 2022 | 15,789 | 74,160 (0%) | 0% | 289.0 | 4,563,653 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 12,141 | 89,949 (0%) | 0% | 227.9 | 2,766,448 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 8,236 | 102,090 (0%) | 0% | 232.5 | 1,914,952 | Common Stock |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 28,444 | 78,232 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,928 | 99,160 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 17,445 | 116,605 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Jeffrey M Leiden | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.63 per share. | 01 Feb 2022 | 6,279 | 110,326 (0%) | 0% | 243.6 | 1,529,753 | Common Stock |